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Congenital adrenal hyperplasia (CAH) is a group of autosomal 
recessive disorders characterised by enzyme deficiencies that impair 
adrenal steroid biosynthesis. The most common form is deficiency of 
the 21-hydroxylase (21-OH) enzyme, accounting for >90% of cases. 
The incidence ranges from 1:10 000 to 1:20 000 live births.[1]
There are three types of CAH, depending on the severity of the 
enzyme deficiency. The most common type is the classic salt-wasting 
(CSW) form, occurring in 75% of cases, which is characterised 
by cortisol and aldosterone deficiency and androgen excess. The 
simple virilising (SV) type is characterised by cortisol deficiency and 
androgen excess but adequate amounts of aldosterone. In both CSW 
and SV CAH, the excess androgens cause virilisation of the genitalia 
in girls, leading to disorders of sex development (DSD). The cortisol 
deficiency may present with an adrenal crisis, while the aldosterone 
deficiency causes sodium and water loss resulting in dehydration, 
shock and electrolyte abnormalities. In addition to the CSW and SV 
forms of CAH, there is also a non-classic form (NCCAH), which is 
characterised by mild deficiency of the 21-OH enzyme with variable 
degrees of postnatal androgen excess but is sometimes asymptomatic. 
Girls with the NCCAH form are therefore not virilised at birth and 
do not present with DSD. There is mild subclinical impairment of 
cortisol in NCCAH that does not lead to adrenal crises. NC forms 
of CAH are more common than classic forms, occurring in 1 - 3% 
of the general population, and are often misdiagnosed as precocious 
pubarche or polycystic ovarian disease in young women.[1] Newborn 
screening in developed countries has reduced the morbidity and 
mortality associated with CAH.[2]
There is a lack of reporting on the prevalence of CAH in resource-
poor countries such as South Africa (SA), affecting diagnosis, 
treatment and management outcomes. Lack of screening facilities 
results in delayed and missed diagnosis and a high mortality in salt-
wasting forms.
In 1976, Geefhuysen et al.[3] reported that CAH was less common 
in black compared with white SA children. We recently reported 
that CAH was the third most common diagnosis in children with 
DSD attending a specialised endocrine unit.[4] In 2008, Osifo and 
Nwashilliv[5] retrospectively reported on 27 children with CAH in 
Nigeria, highlighting the challenges of managing these children in a 
developing country. Tayel et al.[6] reported a high prevalence of CAH 
in Alexandria, Egypt, justifying the need for a newborn screening 
programme.
In a large retrospective population-based cohort study in Sweden,[7] 
the authors concluded that diagnoses in boys and girls with CAH 
were equally missed and that neonatal screening improved detection 
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Background. Congenital adrenal hyperplasia (CAH) caused by deficiency of the 21-hydoxylase (21-OH) enzyme is the most common form 
of CAH worldwide.
Objective. To evaluate the prevalence of CAH due to 21-OH deficiency, and its clinical presentation and biochemical profiles in affected 
children.
Methods. We performed a retrospective subset analysis of 44 children with confirmed CAH.
Results. All the children had classic CAH. The majority (59.8%) had classic salt-wasting (CSW) CAH and 40.1% had simple virili sing (SV) 
CAH. The median age of presentation was 8.1 years (interquartile range (IQR) 4.5 - 11) in the SV group and 2 months (IQR 2 weeks - 5 months) in 
the CSW group (p=0.0001). No difference in age of presentation was noted between males and females (p=0.541). The clinical presentation 
was significantly different between the CSW and SV groups, and between males and females in the CSW group (p<0.0001). Most of the 
females with 46,XX CSW CAH (66.7%) presented with disorders of sex development (DSD), while the remaining 33.3% presented with 
DSD and dehydration and shock. All the males with 46,XY CSW CAH presented with dehydration and shock. Overall, 37.9% (11/29) of the 
children were obese or overweight at presentation. Gonadotrophin-releasing hormone-dependent central precocious puberty was observed 
on follow-up in 29.4% (10/34) of the children at a median of 6.7 years (IQR 5 - 7.7).
Conclusion. The diagnosis of CAH is delayed in males and females in both SV and CSW forms of the disorder, which probably contributes 
to under-reporting of cases and a high mortality rate.
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rates. However, in other European studies in which CAH was 
diagnosed clinically, the diagnosis was missed in males more than 
in females.[8-10]
Objective
Retrospective evaluation of the prevalence, clinical presentation and 
biochemical profiles of CAH caused by 21-OH deficiency in children 
attending a tertiary hospital in Durban, SA.
Methods
A database of patients with DSD presenting to the endocrine unit at 
Inkosi Albert Luthuli Central Hospital (IALCH) in Durban has been 
maintained from January 1995. This database was used to analyse 
the past records of patients with DSD. The database obtained class 
approval from the Biomedical Research and Ethics Council (ref. no. 
BE479/14) in 2015.
IALCH is a provincial tertiary hospital in KwaZulu-Natal Province 
(KZN) and serves a population of ~5 million children from 11 health 
districts. It is the only referral centre for paediatric patients with 
endocrine problems in KZN. Children are initially evaluated at their 
district or regional hospitals and referred to IALCH for subspecialist 
support. This is a retrospective review of a subset of children with a 
diagnosis of CAH made by the paediatric endocrinologist, based on 
clinical presentation and confirmed with biochemical investigations.
The following information was recorded in the database: age at 
presentation, birth weight, demographics including residential areas 
and referral hospitals, sex of rearing, gender dysphoria, consanguinity 
and a family history of DSD. Clinical symptoms and presentation of 
the patients were also recorded. Patients were noted as presenting 
with DSD alone, DSD with dehydration and shock, dehydration and 
shock without DSD, precocious puberty or amenorrhoea.
Clinical findings at presentation, including anthropometry 
(height or length, weight and body mass index (BMI) z-scores), 
were recorded. The patients’ nutritional status was classified using 
the World Health Organization (WHO) child growth reference 
standards.[11] Overweight was defined as a z-score ≥1 SDS (standard 
deviation score) and obesity as a z-score ≥2 SDS above the WHO 
growth reference median. Pubertal stage was assessed using the 
Tanner scale. The Prader scoring system was used to determine the 
degree of external virilisation.[12]
Karyotyping was performed in all patients on peripheral blood 
leucocytes. The biochemical diagnosis of 21-OH deficiency was 
confirmed by hormonal evaluation. The patients’ biochemical values 
(serum electrolytes and blood glucose) and levels of sex steroids 
at presentation, before the initiation of hormone replacement, 
were measured. Gonadotrophins, 17-hydroxyprogesterone (17-
OHP), dehydroepiandrostenedione (DHEA-S), androstenedione, 
testosterone and oestradiol were recorded. All hormone levels 
were assayed with commercially available kits. Sex steroids and 
adrenocorticotrophic hormone (ACTH) were measured using 
chemiluminescence radioimmunoassay (Immulite 2000, Siemens, 
USA) in a central laboratory at IALCH. Plasma renin (mass) 
was measured by Cisbio radioimmunoassay (Cisbio, France), and 
serum aldosterone and 17-OHP were measured by Beckman coulter 
radioimmunoassay (Beckman Coulter, USA). Results were quantified 
using the Cobra II gamma counter (Packard, USA). Reference 
values are highly method dependent. Our unit has established 
its own normal values in conjunction with the local and regional 
laboratories. Values were compared with age- and sex-matched data 
from unaffected children.
An early-morning (before 08h00) baseline serum 17-OHP level is 
the screening test of choice in symptomatic individuals after infancy. 
Reference ranges of 17-OHP were 0.2 - 2.3 nmol/L for newborns and 
infants, 0.1 - 2.7 nmol/L for prepubertal children, 0.1 - 5.4 nmol/L for 
pubertal boys, 0.1 - 8 nmol/L for pubertal girls, 0.4 - 2.1 nmol/L for 
post-menarche girls during the follicular phase, and 1.0 - 8.7 nmol/L 
for post-menarche girls during the luteal phase.[13,14]
A screening serum 17-OHP level of >6 nmol/L was an indication 
to obtain a complete adrenocortical profile and to perform a high-
dose (250 µg) cosyntropin stimulation test (HDSST). The HDSST 
is the gold standard to differentiate 21-OH deficiency from other 
enzyme defects and to confirm the diagnosis in borderline cases.[15]
Levels of 17-OHP and cortisol were measured at baseline, then 
30 and 60 minutes after the administration of cosyntropin. The 
plasma cortisol level at 30 minutes should be >550 nmol/L. A normal 
response to cosyntropin is an incremental increase of <10  nmol/L 
above basal concentration at 60 minutes. Patients with NC CAH 
show an incremental increase of >20 nmol/L, while heterozygote 
CAH patients have an intermediate response with considerable 
overlap into the normal range.[15] The 17-OHP values were plotted on 
a nomogram to determine the severity of the disease.[16] Unfortunately 
cosyntropin was not easily available, and we were unable to perform 
the test on an urgent basis in some patients. These patients were 
treated according to the clinical findings and supportive baseline 
biochemical results. Molecular genetic analysis is also not routinely 
available for patients with DSD and CAH in SA.
Findings on radiological investigations, including the findings of a 
pelvic ultrasound scan, and bone age were also captured.
Patients were divided into CSW and SV groups, and further 
subdivided according to karyotypes. The clinical characteristics and 
biochemical values were compared between and within the groups.
The diagnosis of central precocious puberty (CPP) was made 
clinically and was supported by biochemical findings. Puberty that 
begins before 8 years of age in girls and before 9 years of age in boys 
is defined as precocious puberty. In girls, the first sign of puberty is 
usually breast enlargement, which may initially be unilateral. Pubic 
and axillary hair may appear before, at about the same time as, or 
well after the appearance of breast tissue. Menarche is a late event 
and does not usually occur until 2 - 3 years after onset of breast 
enlargement. In boys, the earliest evidence of puberty is testicular 
enlargement (>4 mL). This is followed by growth of the penis 
and scrotum, which typically occurs at least a year after testicular 
enlargement. Measurement of serum testosterone is useful in boys 
with suspected precocious puberty. A luteinising hormone level 
of <0.1 IU/L is generally prepubertal. Random follicle-stimulating 
hormone levels do not discriminate between prepubertal and 
pubertal children.
Statistical analysis
Data were analysed using Stata version 14 (StataCorp, USA). Cate-
gorical variables were described using frequencies and percentages, 
and associations between groups were tested using Pearson’s χ2 
test or Fisher’s exact test, where applicable. Continuous variables 
were described using medians with interquartile ranges (IQRs), 
and differences between groups were tested using the Kruskal-
Wallis test. Spearman correlations were computed between age and 
sex steroids. Results were considered statistically significant for 
p-values <0.05.
Results
A total of 3 233 patients attended the endocrine clinic over the review 
period, and 44 (1.4%; 95% confidence interval 0.99 - 1.82) had a 
diagnosis of CAH. Thirty-nine patients were diagnosed between the 
years 2006 and 2016.
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All the patients (N=44) were diagnosed with classic CAH (Table  1). 
The majority (59.8%, n=26) had CSW CAH, and 40.9% (n=18) had 
SV CAH. Overall, there were more females (80.8%) than males 
(19.2%) among the classic CAH patients. There was no significant 
gender difference between the CSW and SV groups (p=0.999).
Age at presentation
The diagnosis was established significantly later in the SV CAH 
group (median 8.1 years (IQR 4.5 - 11)) than in the CSW CAH 
group (median 2 months (IQR 2 weeks - 5 months)) (p=0.0001). The 
median age at presentation in the 46,XY CSW group was 3 months 
(IQR 3 - 4), while that in the 46,XX CSW group was 1 month (IQR 2 - 
5) (p=0.241). In the 46,XY SV group the median age of presentation 
was 7 years (IQR 5.5 - 9.5), and in the 46,XX SV group it was 9.2 years 
(IQR 4.3 - 10.8) (p=0.832). There was no significant difference in 
median age of presentation between females and males (p=0.541) in 
the CSW and SV groups (Fig. 1).
Baseline demographic characteristics
Baseline and demographic characteristics of the cohort are 
summarised in Table 1. There was no family history of consanguinity 
among the patients with CAH. A positive family history of CAH was 
noted in 13.6% of patients (n=6), or three families. In the first family, 
the sibling pair each had 46,XX CSW CAH, while in the second 
family, the siblings had 46,XX SV CAH. In the third family, two 
siblings were diagnosed with CAH; however, the older sibling had 
46,XY SV CAH and the younger sibling 46,XX CSW CAH.
Baseline clinical characteristics
The clinical presentation was substantially different between the 
two groups (p<0.001) (Table 2). In the CSW group, 14/21 patients 
(66.6%) presented with DSD without dehydration and shock, while 
7/21 (33.3%) presented with DSD and dehydration and shock. This 
difference was also significant between the males and females in the 
CSW group (p<0.001). Most of the females with 46,XX CSW (66.6%) 
were noted to have DSD on routine neonatal examination. None 
of the males with 46,XY CSW presented with DSD in the neonatal 
period. All the males (n=5) presented with dehydration and shock. 
In the SV group, 12 patients (66.7%) presented with precocious 
puberty and 5/14 females (35.7%) presented with DSD. The clinical 
presentation between male and females in the SV CAH group did not 
differ significantly (p=0.425).
Birth weight was recorded in 41 patients. More patients in the 
CSW group were of low birth weight compared with the SV group 
Table 1. Baseline demographics and clinical characteristics of patients with CAH
CSW CAH (N=26), 
n (%)
SV CAH (N=18), 
n (%) p-value
Karyotype 0.999
46,XX 21 (80.8) 14 (77.8)
46,XY 5 (19.2) 4 (22.2)
Population group 0.582
Black African 23 (88.5) 16 (89.0)
Indian 3 (11.5) 1 (5.5
White 0 1 (5.5)
Mixed 0 0
Family history 3 (11.5) 3 (16.7) 0.423
Birth weight* 0.039
Term 16 (64.0 15 (93.8)
Low birth weight 7 (28.0) 0
Very low birth weight 2 (8.0) 1 (6.2)
Anthropometry† <0.001
Overweight 0 6 (54.5)
Obese 0 5 (45.4)
Severe acute malnutrition 18 (100) 0
Prader score 0.999
1 1 (3.8) 0
2 1 (3.8) 0
3 10 (38.5) 7 (38.9)
4 8 (30.8) 7 38.9)
5 6 (23.1) 4 (22.2)
CAH = congenital adrenal hyperplasia; CSW = classic salt wasting; SV = simple virilising.
*Based on 25 CSW CAH and 16 SV CAH.














46,XY DSD             46,XX DSD
SV CAH
46,XY DSD             46,XX DSD
CSW CAH
CSW CAH v. SV CAH: p=0.0001
Fig. 1. Age of the patients at presentation. (CAH = congenital adrenal 
hyperplasia; CSW = classic salt-wasting; SV = simple virilising; DSD = 
disorder of sexual development.)
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(p=0.039). No association was found between karyotype and birth 
weights within the two groups.
Anthropometric data were available for 29 patients (65.9%). 
Overall, 37.9% (n=11) of these were either obese or overweight. 
All the obese patients were black females. Compared with SV 
patients, notably more CSW patients (62.1%, n=18) had severe acute 
malnutrition. SV patients were more likely to be obese (n=5, 45.5%) 
or overweight (n=6, 54.5%) at presentation (p<0.001).
The median total daily dose of hydrocortisone was 15 mg/m2/d 
(IQR 10 - 16) in the CSW group and 12 mg/m2/d (IQR 11 - 15) in the 
SV group (p=0.251).
Baseline biochemical findings
There was a significant difference in serum sodium, potassium, 
bicarbonate, renin, aldosterone and DHEA-S levels between the CSW 
and SV groups (Table 3). The most significant difference between 
the two groups was in serum potassium and renin levels (p<0.0001). 
There was a significant negative correlation between sex steroids 
and age in the CSW group (Table 4). The younger patients in the 
CSW group tended to have higher sex steroid levels. No significant 
correlation was found in the SV group except for DHEA-S levels, 
which increased with age (p<0.008).
High-dose cosyntropin stimulation test
The HDSST test was performed in 20 (45.5%) of the patients (9 in the 
CSW group and 11 in the SV group). The median age at which the test 
was done was 3 months (IQR 1 - 6) in the CSW group and 7.5 years 
(IQR 4.8 - 9.7) in the SV group (p=0.002). There was no significant 
difference in serum 17-OHP and cortisol levels at baseline and at 
30 and 60 minutes between the two groups. The maximum serum 
17-OHP level (noted at 30 minutes) was 1 057 mmol/L (IQR 664 - 
1 450) in the CSW group and 286.5 mmol/L (IQR 186 - 387) in the 
SV group. The serum cortisol level at 30 minutes was 222.5 mmol/L 
(140 - 368) in the CSW group and 160 mmol/L (145 - 221) in the SV 
group, confirming cortisol deficiency.
Central precocious puberty
Gonadotrophin-releasing hormone (GnRH)-dependent CPP was 
observed on follow-up in 10/34 patients (29.4%) at a median of 6.4 years 
(IQR 6.2 - 7.7) in girls and 7 years (IQR 6.7 - 7.4) years in boys (p=0.602). 
CPP was observed in five patients with SV CAH and five patients with 
CSW CAH. Of the patients with CPP, 60.0% had the female karyotype. 
There was no association between CPP and age at presentation, total 
daily dose of hydrocortisone, baseline gonadotrophins and sex steroids 
compared with patients who did not develop CPP.
Table 3. Biochemical values in patients with CAH
Biochemical value CSW CAH, median (IQR) SV CAH, median (IQR) p-value
Sodium (mmol/L)† 134 (124 - 139) 140 (137 - 141) 0.0010*
Potassium (mmol/L)† 6.7 (5.7 - 7.4) 4.3 (4.0 - 4.8) 0.0001*
Bicarbonate (mmol/L)† 20 (16 - 23) 25 (23 - 26) 0.0002*
Glucose (mmol/L)† 5 (4 - 5) 5 (4 - 6) 0.3390
ACTH (pmol/L)† 80.9 (26.6 - 154.0) 39.3 (16.6 - 75.3) 0.1220
Cortisol (nmol/L)† 135 (62 - 254) 146 (102 - 189) 0.6760
Plasma renin activity (pmol/L)† 612 (222 - 1 340) 58 (23 - 127) 0.0001*
Aldosterone (pmol/L)† 2 025 (1 129 - 3 300) 763 (259 - 1 120) 0.0020*
17-OHP (nmol/L)‡ 86.5 (37.0 - 135.0) 116.0 (30.6 - 307.4) 0.6440
DHEA-S (µmol/L)† 1.1 (0.3 - 4.5) 5 (2 - 11) 0.0030*
Androstenedione (nmol/L)† 30 (19 - 35) 35 (17 - 35) 0.9360
Testosterone (nmol/L)† 5 (3 - 16) 6 (4 - 8) 0.7700
FSH (mIU/mL)† 0.5 (0.3 - 3.2) 0.8 (0.3 - 3.2) 0.6560
LH (mIU/mL)† 0.1 (0.1 - 0.7) 0.1 (0.1 - 0.4) 0.8120
CAH = congenital adrenal hyperplasia; CSW = classic salt wasting; SV = simple virilising; DSD = disorder of sexual development; IQR = interquartile range; ACTH = adrenocorticotrophic 
hormone; 17-OHP = 17-hydroxyprogesterone; DHEA-S = dehydroepiandrostenedione; FSH = follicle-stimulating hormone; LH = luteinising hormone.
*Statistically significant at the 5% level.
†Reference ranges are highly method dependent, corrected for age, sex and pubertal stage:[22] sodium (mmol/L): up to 1 month 130 - 145, >1 month 135 - 145; potassium (mmol/L): up to 1 month 
3.5 - 6.0, >1 month 3.4 - 5.0; bicarbonate (mmol/L): 1 - 4 years 17 - 25, 4 - 8 years 19 - 27, >8 years 21 - 29; glucose (mmol/L): birth to 1 month 2.5 - 5.5, child 3.0 - 6.1; ACTH (pmol/L) <18; 
serum cortisol (nmol/L): 09h00 200 - 700, 24h00 (sleeping) <50 ; plasma renin activity (pmol/L): supine 6.5 - 36.2, upright 9.2 - 69.7; aldosterone (pmol/L): birth - 1 week up to 5 000, 1 week - 
1 year 300 - 1 500, 1 - 2 years 200 - 1 500, 2 - 10 years 100 - 800, 10 - 15 years 60 - 600; DHEA-S (µmol/L): females <8 years <0.6, 8 - 10 years 0.3 - 1.6, 10 - 12 years 0.8 - 3.2, >12 years 1 - 5; males 
<8 years <0.6, 8 - 10 years 0.2 - 2.8, 10 - 12 years 0.9 - 3.8, >12 years 2 - 10; androstenedione (nmol/L): prepubertal 0.3 - 1.8, pubertal 2 - 8; testosterone (nmol/L): week 1 0.5 - 1.5, 15 - 60 days 
<0.5, prepubertal (from 7 months) <0.5; FSH (mIU/mL): female prepubertal 0.4 - 3.0, male prepubertal 0.4 - 1.6;  LH (mIU/mL): female and male prepubertal <0.5.
‡Reference ranges for 17-OHP (nmol/L):[13,14] 0.2 - 2.3 newborns and infants, 0.1 - 2.7 prepubertal children, 0.1 - 5.4 pubertal boys, 0.1 - 8 pubertal girls, 0.4 - 2.1 post-menarche girls (follicular 
phase), 1.0 - 8.7 post-menarche girls (luteal phase).
Table 2. Clinical presentation of patients with CAH*
CSW CAH (N=26), 
n (%)
SV CAH (N=18), 
n (%)
46,XX 46,XY 46,XX 46,XY
DSD without dehydration and shock 14 (66.7) 0 5 (35.7) 0
DSD with dehydration and shock 7 (33.3) 0 0 0
Precocious puberty 0 0 8 (57.1) 4 (100)
Dehydration and shock without DSD 0 5 (100) 0 0
Amenorrhoea 0 0 1 (7.2) 0
p-value between karyotypes <0.001 0.425
CAH = congenital adrenal hyperplasia; CSW = classic salt wasting; SV = simple virilising; DSD = disorder of sexual development.
*Significant difference in clinical presentation between CSW CAH v. SV CAH (p<0.001).
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Discussion
In this retrospective review over more than 20 years, we have shown 
that CAH caused by a deficiency of the 21-OH enzyme is not as 
common as might be expected among black children in KZN, SA.
All the patients had classic CAH and none had the mild NC form. 
Although NC forms of CAH are more prevalent than classic CAH 
in the general population, they present later in adolescence and 
adulthood. In our unit at IALCH, as per hospital policy, patients 
aged >12 years are referred to the adult units for management, which 
would explain the lack of patients with NCCAH.
As expected, CSW CAH presented significantly earlier than SV 
CAH. Overall there were fewer males than females, which could 
reflect unreported deaths in males in whom the diagnosis of CAH 
was missed. Although females with CSW CAH presented earlier 
than males, the median age of presentation was not significantly 
different between the two groups. This is similar to findings from the 
large population-based cohort study in Sweden,[7] but contrasts with 
reports from most studies in Europe in the pre-screening era, where 
females with CAH presented significantly earlier than males. [8-10] 
In resource-poor settings, especially in the absence of neonatal 
screening, examination of the genitalia is crucial in detecting children 
with CAH. Virilisation of the external genitalia without palpable 
gonads should arouse the suspicion of CAH and is an indication for 
prompt and emergency referral to an endocrine specialist.
It is known that female infants with CAH present with life-
threatening adrenal crises in the second week, and males by the third 
week.[8] Although two-thirds of females in our study were diagnosed 
with DSD in the neonatal period, a third with DSD were missed 
or not recognised and subsequently presented with dehydration, 
salt loss and shock. All the males in the CSW group presented with 
dehydration and shock. Males have a lack of genital ambiguity that 
can lead to a delayed or missed diagnosis. However, females have 
virilisation of the external genitalia and should be recognised at birth. 
The death rate in CSW CAH without screening is 4 - 10%. Early 
diagnosis and treatment can prevent this mortality and morbidity, 
which has been averted in developed countries, where screening for 
CAH is universal.[14] Neonatal screening for 21-OH deficiency is not 
routinely available in SA.
There was a significant difference in growth parameters between 
the CSW and SV CAH groups. In the CSW CAH children, ongoing 
salt loss and dehydration results in malnutrition. Failure to thrive 
has previously been described in CSW CAH.[17] In contrast, all 
the patients in the SV group were either overweight or obese, and 
specifically all black females were obese. The majority of the patients 
in the SV group presented with precocious puberty. An increase in 
BMI has been associated with early puberty.[18]  In some studies, the 
association is stronger in white girls than in black girls.  However, 
obesity  is not clearly associated with early puberty in boys or girls. 
The prevalence of childhood overweight and obesity in SA is one of 
the highest in Africa. The high frequency of obesity in the SV group 
may therefore be an indication of the background obesity epidemic 
in SA.
Both CSW and SV CAH are associated with impaired cortisol 
synthesis. The 21-OH enzyme converts 17-hydroxyprogesterone to 
11-deoxycortisol and progesterone to deoxycorticosterone, which 
are precursors for cortisol and aldosterone synthesis. In CSW CAH 
characterised by a severe deficiency of the 21-OH enzyme, both 
cortisol and aldosterone are deficient. The biochemical profile is 
characterised by hyponatraemia, hyperkalaemia, low serum cortisol 
and aldosterone and high plasma renin and ACTH. Gastroenteritis is 
common in SA and can present with similar electrolyte abnormalities to 
CAH, which can mask diagnosis of the latter. Healthcare professionals 
should therefore have a high index of suspicion of CAH in children 
who present with hyponatraemia and hyperkalaemia. In SV CAH, 
however, serum sodium, potassium, aldosterone and renin levels 
are normal.[1] The finding of significantly different plasma renin and 
potassium levels between the groups is therefore to be expected and is 
secondary to the aldosterone deficiency in the CSW group.
Adrenal sex steroids, especially androstenedione and to a lesser 
extent testosterone, are elevated in 21-OH deficiency owing to the 
accumulation of cortisol precursors that are diverted to sex hormone 
synthesis. There was no significant difference in testosterone and 
androstenedione levels between the two groups in our study, but there 
was a significant difference in DHEA-S levels. This can be explained 
by age-related differences between the two groups, as serum levels of 
DHEA-S increase with age and the mean age was higher in the SV 
group. The back-door pathway is also more dominant in SW CAH, 
hence the lower DHEA-S levels.[19] DHEA-S is not a good marker 
of 21-OH activity, as it binds with high-affinity albumin, has a long 
plasma half-life and is not responsive to acute change or to ACTH 
stimulation.[1] The younger patients in the CSW group tended to 
have higher sex steroid levels than the older patients in the SV group, 
reflecting the mini-puberty of infancy.
While patients with SV CAH are known to present with 
peripheral precocious puberty, CPP caused by premature activation 
of the hypothalamic-pituitary gonadal axis is also described in 
patients with CAH. The CPP is triggered by the chronic mild to 
moderate intermittent elevation of androgens in patients who are 
non-compliant with medication. SV boys with advanced bone 
age of >12 years may have spontaneous CPP when treatment 
with hydrocortisone is initiated. The hydrocortisone suppresses 
the production of adrenal androgens and stimulates the release of 
gonadotrophins if hypothalamic maturation is already present.[20,21] 
All our patients with CPP are receiving treatment with a GnRH 
analogue. In SA, considerable limitations exist in optimally managing 
this condition. These include cultural and social issues, such as 
stigma and shame associated with genital abnormalities, that affect 
adherence to treatment.
Study limitations
This is a retrospective descriptive study, which is accompanied 
by the usual issues of data integrity such as missing data. To our 
knowledge, however, this review is the first and largest study 
evaluating the prevalence, clinical presentation and biochemical 
profiles in children with CAH due to 21-OH deficiency in SA. The 
information generated has important implications, as it can be used 
to develop guidelines including a neonatal screening programme for 
CAH to prevent deaths from adrenal crisis in unrecognised patients.
Conclusion
There are limited published data on CAH in SA. CAH caused by 
21-OH deficiency appears to be infrequent in black SA children. In 
Table 4. Correlation between age and hormone level in 
patients with CAH*
Hormone CSW CAH SV CAH
DHEA-S (µmol/L) –0.58 (p=0.004) 0.57 (p=0.008)
Androstenedione (nmol/L) –0.53 (p=0.008) 0.39 (p=0.092)
Testosterone (nmol/L) –0.68 (p=0.0003) 0.23 (p=0.325)
17-OHP (mmol/L) –0.69 (p=0.041) 0.49 (p=0.329)
CAH = congenital adrenal hyperplasia; CSW = classic salt wasting; SV = simple virilising; 
DHEA-S = dehydroepiandrostenedione; 17-OHP = 17-hydroxyprogesterone.
*In the CSW group, an increase in age is associated with lower hormone levels; in the SV 
group, an increase in age is associated with increased DHEA-S levels.
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our cohort, the diagnosis of CAH was delayed in males and females 
in both the SV and CSW groups. One-third of females with genital 
ambiguity were missed at birth and presented with life-threatening 
adrenal crises. This missed and delayed diagnosis probably results in 
a high mortality rate and under-reporting of cases. In the absence of 
neonatal screening for CAH in SA, there is an urgent need to educate 
and train healthcare workers to recognise neonates with DSD early 
and refer them timeously for specialist care.
Acknowledgements. None.
Author contributions. All the authors accept responsibility for the entire 
content of the submitted manuscript and approved its submission.
Funding. None.
Conflicts of interest None.
1. Speiser WP. Congenital adrenal hyperplasia owing to 21-hydroxylase deficiency. Endocrinol Metab 
Clin North Am 2001;30(1):31-59. https://doi.org/10.1016/S0889-8529(08)70018-5
2. Therell BL. Newborn screening for congenital adrenal hyperplasia. Endocrinol Metab Clin North Am 
2001;30(1):15-30. https://doi.org/10.1016/S0889-8529(08)70017-3
3. Geefhuysen J, Hall DMB, Worlfsdorf J. Congenital adrenal hyperplasia in blacks. S Afr Med J 
1976;50(22):851-853. 
4. Ganie Y, Aldous C, Balakrishna Y, Wiersma R. Disorders of sex development in children in KwaZulu-
Natal Durban South Africa: 20-year experience in a tertiary centre. J Pediatr Endocrinol Metab 
2017;30(1):11-18. https://doi.org/10.1515/jpem-2016-0152
5. Osifo OD, Nwashilliv NJ. Congenital adrenal hyperplasia: The challenges of management in a 
developing country. Afr J Urol 2008;14(3):138-142. Retrieved from https://www.ajol.info/index.php/
aju/article/view/8241 (accessed 2 January 2018).
6. Tayel SM, Ismael H, Kandil H, Abd Rabuh A, Sallam H. Congenital adrenal hyperplasia in Alexandria, 
Egypt: High prevalence justifying the need for a community based newborn screening program. J 
Tropic Pediatr 2011;57(3):232-234. https://doi.org/10.1093/tropej/fmq064
7. Gildof S, Falhammar H, Guthenberg C, et al. One hundred years of congenital adrenal hyperplasia in 
Sweden: A retrospective population based cohort study. JAMA Pediatr 2014;168(6):567-574. https://
doi.org/10.1001/jamapediatrics.2013.5321
8. Phyllis WS, Ricardo A, Laurence SB, et al. Congenital adrenal hyperplasia due to steroid 
21-hydroxylase deficiency: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 
2010;95(9):4133-4160. https://doi.org/10.1210/jc.2009-2631
9. Lebovitz RM, Pauli RM, Laxova R. Delayed diagnosis in congenital adrenal hyperplasia: 
Need for newborn screening. Am J Dis Child 1984;138(6):571-573. https://doi.org/10.1001/
archpedi.1984.02140440055014
10. Kovács J, Votava F, Heinze G, Sólyom J, et al. Lessons from 30 years of clinical diagnosis and treatment 
of congenital adrenal hyperplasia in five middle European countries. J Clin Endocrinol Metab 
2001;86(7):2958-2964. https://doi.org/10.1210/jcem.86.7.7638 
11. World Health Organization. Child Growth Standards. Geneva: WHO, 2017. http://www.who.int/
childgrowth/en/ (accessed 16 January 2016).
12. White PC, Speiser PW. Congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Endocr Rev 
2000;21(3):245-291. https://doi.org/10.1210/edrv.21.3.0398
13. Hughes IA, Riad-Fahmy D, Griffiths K. Plasma 17OH-progesterone concentrations in newborn 
infants. Arch Dis Child 1979;54(5):347-349.
14. Orth D, Kovacs D, DeBold C. The adrenal cortex. In: Wilson JH, Foster DW, eds. Williams Textbook of 
Endocrinology. 8th ed. Philadelphia: WB Saunders, 1992.
15. Lashansky G, Saenger P, Fishman K, et al. Normative data for adrenal steroidgenesis in a healthy 
paediatric population: Age and sex related changes after ACTH stimulation. J Clin Endocrinol Metab 
1991;73(3):674-686. https://doi.org/10.1210/jcem-73-3-674
16. New MI, Lorenzen F, Lerner AJ, et al. Genotyping steroid 21-hydroxylase deficiency: Hormonal 
reference data. J Clin Endocrinol Metab 1983;57(2):320-326. https://doi.org/10.1210/jcem-57-2-320
17. Sopfe J, Simmons JH. Failure to thrive, hyponatremia, and hyperkalemia in a neonate. Pediatr Ann 
2013;42(5):74-79. https://doi.org/10.3928/00904481-20130426-09
18. Mamun AA, Hayatbakhsh MR, O’Callaghan M, Williams G, Nauman J. Early overweight and pubertal 
maturation – pathways of association with young adults’ overweight: A longitudinal study. Int J Obes 
(Lond) 2009;33(1):14-20. https://doi.org/10.1038/ijo.2008.220
19. Turcu AF, Auchus RJ. Adrenal steroidgenesis and congenital adrenal hyperplasia. Endocrinol Metab 
Clin North Am 2015;44(2):275-296. https://doi.org/10.1016/j.ecl.2015.02.002
20. Oyenusi EE, Oduwole AO, Kooris OO, Ademola AO, Nwaogu NT, Sabotages SB. Congenital adrenal 
hyperplasia at the Lagos University Teaching Hospital: A 10‑year review. J Clin Sci 2016;13(4):178‑186. 
https://doi.org/10.4103/2468-6859.192291
21. Guven A, Cebeci N, Hancili S. Gonadotropin releasing hormone analogue treatment in children 
with congenital adrenal hyperplasia complicated by central precocious puberty. Hormones (Athens) 
2015;14(2):265-271. https://doi.org/10.14310/horm.2002.1555
22. Lesley J, Tetlow, Clayton P, Brook C. Tests and normal values in pediatric endocrinology. In: Brook C, 
Clayton P, Brown R, eds. Brook’s Clinical Pediatric Endocrinology. 5th ed. Oxford. Blackwell 
Publishing, 2005:523-564.
Accepted 20 September 2017.
